{
    "organizations": [],
    "uuid": "1a9a69cc6ed4e53ca78625d9b5bf7ea422429e6d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-mdxhealth-develops-blood-test-for/brief-mdxhealth-develops-blood-test-for-prostate-cancer-patients-idUSFWN1PD05O",
    "ord_in_thread": 0,
    "title": "BRIEF-MDxHealth ‍Develops Blood Test For Prostate Cancer Patients​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 18 (Reuters) - MDXHEALTH SA:\n* ‍DEVELOPS BLOOD TEST TO GUIDE PRECISION-TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER PATIENTS​\n* STUDY DEMONSTRATES TEST CAN ADD PROGNOSTIC INFORMATION ON OVERALL SURVIVAL\n* ‍EARLIER ASSESSMENT OF TREATMENT RESPONSE CAN HELP IDENTIFY RESISTANCE SOONER​\n* OVER 233,000 CRPC PATIENTS UNDER TREATMENT GLOBALLY EACH YEAR Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-18T14:15:00.000+02:00",
    "crawled": "2018-01-19T12:25:40.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "mdxhealth",
        "sa",
        "blood",
        "test",
        "guide",
        "prostate",
        "cancer",
        "study",
        "demonstrates",
        "test",
        "add",
        "prognostic",
        "information",
        "overall",
        "survival",
        "assessment",
        "treatment",
        "response",
        "help",
        "identify",
        "resistance",
        "crpc",
        "patient",
        "treatment",
        "globally",
        "year",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}